Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity
2019
Neoantigen burden is a major determinant of tumor immunogenicity, underscored by recent clinical experience with checkpoint blockade therapy. Yet the majority of patients do not express, or express too few, neoantigens, and hence are less responsive to immune therapy. Here we describe an approach whereby a common set of new antigens are induced in tumor cells in situ by transient downregulation of the
transporter associatedwith
antigen processing(
TAP). Administration of
TAPsiRNA conjugated to a broad-range tumor-targeting
nucleolin
aptamerinhibited tumor growth in multiple tumor models without measurable toxicity, was comparatively effective to vaccination against prototypic mutation-generated neoantigens, potentiated the antitumor effect of PD-1 antibody or
Flt3 ligand, and induced the presentation of a
TAP-independent peptide in human tumor cells. Treatment with the chemically-synthesized
nucleolin
aptamer-
TAPsiRNA conjugate represents a broadly-applicable approach to increase the antigenicity of tumor lesions and thereby enhance the effectiveness of immune potentiating therapies. The anti-tumour immune response greatly depends on the number of tumour neoantigens. Here the authors show in mouse models that a therapeutic strategy aimed at increasing the number of neoantigens via downregulating
TAP, an
antigen processingassociated protein, enhances anti-tumour immunity and the efficacy of immunotherapy.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
57
References
20
Citations
NaN
KQI